Companies › Aspeya
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology, Respiratory; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ASY202 Dihydroergotamine (DHE) inhalation powder - ergot alkaloid vasoconstrictive agent | – | Phase 2 | Migraine; Safety in Asthma Patients | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07646613 | ASY202 | Phase 2 | Migraine | Neurology | Mar 2027 |
| NCT07665892 | ASY202 | Phase 1 | Safety in Asthma Patients | Respiratory | Mar 2027 |
No annotated target.
–
Biossil Vicore Pharma SpliSense Sundance Biosciences Teikoku Pharma USA
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.